Stephen Archibald

As radiopharmaceutical therapies advance, ensuring patient safety remains paramount. This workshop offers a comprehensive overview of designing novel radiopharmaceuticals with an emphasis on minimising toxicity. We’ll explore the intricacies of molecular designrom targeting moieties to payloads and discuss strategies to mitigate associated toxicities.

• Designing safer tumour-targeted in situ RadioIMmunoStimulants (RIMS) for metastaticcastration resistant prostate cancer
• Disease Biology Insights: Understanding diseasespecific biology to inform safer drug design
• Optimising pharmacokinetics and safety to improve radiation exposure
• Toxicity Exploration: Identifying common toxicities in radiopharmaceuticals and strategies to avoid them across different modalities